Isomorphic Labs Secures $600M to Advance AI-Powered Drug Discovery

The Alphabet subsidiary will use the funding to expand its team, enhance its AI drug design engine, and move closer to clinical trials for AI-designed treatments.

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet.
The funding will accelerate the development of its next-generation AI drug design engine and support its mission to transform drug discovery and address major diseases.
The company plans to expand its workforce and advance its internal programs, including oncology and immunology, toward clinical development by the end of 2025.
Isomorphic Labs leverages DeepMind’s AlphaFold technology, which predicts protein structures, as a cornerstone of its AI-driven drug discovery efforts.
Strategic partnerships with pharmaceutical giants Eli Lilly and Novartis remain central to its efforts, with multi-billion-dollar milestone agreements in place.